<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167074</url>
  </required_header>
  <id_info>
    <org_study_id>ASPRO-2014-01</org_study_id>
    <nct_id>NCT02167074</nct_id>
  </id_info>
  <brief_title>Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS</brief_title>
  <acronym>ASPRO</acronym>
  <official_title>A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Liver Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cook Ireland, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Liver Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the diagnostic accuracy of two EUS-guided tissue
      acquisition devices; the 25G Echotip Ultra Fine Needle Aspiration (FNA) device and the 20G
      Echotip ProCore Fine Needle Biopsy (FNB) device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic ultrasound (EUS)-guided tissue acquisition has emerged as a valuable method to
      diagnose and stage malignancies. During Endoscopic Ultrasound (EUS), tissue samples can be
      obtained for pathological evaluation with different devices. Fine needle aspiration (FNA)
      provides a cytological specimen. Unfortunately, in a cytological specimen, inflammatory
      changes may be undistinguishable from well-differentiated dysplasia. Moreover, for neoplasms
      such as lymphomas and stromal tumors, tissue architecture and cell morphology are essential
      for accurate pathological assessment. Therefore, pathologists generally prefer a histological
      specimen. Fine needle biopsy (FNB) has the advantage of obtaining a histological specimen,
      which may lead to better diagnostic performance. However, FNB needles are stiffer and more
      difficult to handle, which can complicate tissue acquisition. In addition, the superiority of
      histology over cytology in EUS-guided tissue sampling has not been proven yet. For instance,
      tissue, obtained by FNA and processed with the new cell-block technique, may equal the
      diagnostic yield of histological tissue cores.

      A recent meta-analysis suggested that 25G is the optimal FNA needle size to obtain an
      adequate cytological specimen. In this study, we aim to compare the properties and merits of
      a newly designed, more flexible, 20G EUS ProCore FNB device to a conventional 25G EUS-FNA
      device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Accuracy</measure>
    <time_frame>27 months</time_frame>
    <description>Diagnostic accuracy is the number of correctly diagnosed cases as compared to gold standard diagnosis
Gold standard diagnosis is defined as;
in operated patients; based on the surgical resection specimen
in non-operated patients; based on the conclusions of the diagnostic work-up (combined outcomes of tissue sampling and imaging studies), and confirmed by a compatible clinical disease course of at least 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Whom Target Lesion Was Sampled</measure>
    <time_frame>1 day</time_frame>
    <description>records if a target lesion was reached during the procedure using the randomised needle or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Vital Target Cells Per Case, Per Needle Type</measure>
    <time_frame>after 27 months</time_frame>
    <description>Presence of sufficient vital target cells, as in, target organ cells to provide a diagnosis (yes or no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events Per Needle Type</measure>
    <time_frame>27 months after procedure</time_frame>
    <description>adverse events per needle type, up to 27 months after procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Yield of the First Needle Pass</measure>
    <time_frame>after 27 months</time_frame>
    <description>Yield is expressed as sample sufficiency for diagnostic analysis by pathologists, this was either sufficient or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On-site Pathological Evaluation Performed</measure>
    <time_frame>27 months</time_frame>
    <description>Presence of pathologist on site during procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">615</enrollment>
  <condition>Pancreatic Masses</condition>
  <condition>Lymph Nodes</condition>
  <arm_group>
    <arm_group_label>25G FNA needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20G ProCore FNB needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>25G FNA needle</intervention_name>
    <arm_group_label>25G FNA needle</arm_group_label>
    <other_name>25G Echotip Ultra Fine Needle Aspiration (FNA) device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>20G ProCore FNB needle</intervention_name>
    <arm_group_label>20G ProCore FNB needle</arm_group_label>
    <other_name>20G Echotip ProCore Fine Needle Biopsy (FNB) device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients referred for EUS-guided tissue acquisition because of a (I) pancreatic mass
             lesion or (II) lymph node

          -  Age &gt; 18 years

          -  Written informed consent

          -  Lesion can be visualized with EUS and is â‰¥1 cm in size

        Exclusion Criteria:

          -  Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh
             frozen plasma (FFP)

          -  Use of anticoagulants that cannot be discontinued in order to guarantee an INR below
             1.5

          -  Purely cystic lesions

          -  Previous inclusion in the current study

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco J Bruno, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Djuna L Cahen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>CA 92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>CT 06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>NY 11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Salute San Raffaele University</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University Rome</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University</name>
      <address>
        <city>Osaka-sayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Santiago de Compostella</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <results_first_submitted>August 7, 2018</results_first_submitted>
  <results_first_submitted_qc>March 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2020</results_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic accuracy</keyword>
  <keyword>Endoscopic Ultrasound-Guided Fine Needle Aspiration</keyword>
  <keyword>EUS-FNA</keyword>
  <keyword>Endoscopic Ultrasound-Guided Fine Needle Biopsy</keyword>
  <keyword>EUS-FNB</keyword>
  <keyword>Pancreatic mass</keyword>
  <keyword>Lymph node</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 13, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02167074/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02167074/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>3 patients were included but met exclusion criteria 4 patients were lost to follow-up</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>25G FNA Needle</title>
          <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
        </group>
        <group group_id="P2">
          <title>20G ProCore FNB Needle</title>
          <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>25G FNA Needle</title>
          <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
        </group>
        <group group_id="B2">
          <title>20G ProCore FNB Needle</title>
          <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="306"/>
            <count group_id="B2" value="302"/>
            <count group_id="B3" value="608"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="306"/>
                    <count group_id="B2" value="302"/>
                    <count group_id="B3" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="0.7"/>
                    <measurement group_id="B2" value="66" spread="0.7"/>
                    <measurement group_id="B3" value="66" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="306"/>
                    <count group_id="B2" value="302"/>
                    <count group_id="B3" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Accuracy</title>
        <description>Diagnostic accuracy is the number of correctly diagnosed cases as compared to gold standard diagnosis
Gold standard diagnosis is defined as;
in operated patients; based on the surgical resection specimen
in non-operated patients; based on the conclusions of the diagnostic work-up (combined outcomes of tissue sampling and imaging studies), and confirmed by a compatible clinical disease course of at least 9 months</description>
        <time_frame>27 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25G FNA Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
          </group>
          <group group_id="O2">
            <title>20G ProCore FNB Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Accuracy</title>
          <description>Diagnostic accuracy is the number of correctly diagnosed cases as compared to gold standard diagnosis
Gold standard diagnosis is defined as;
in operated patients; based on the surgical resection specimen
in non-operated patients; based on the conclusions of the diagnostic work-up (combined outcomes of tissue sampling and imaging studies), and confirmed by a compatible clinical disease course of at least 9 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="237"/>
                    <measurement group_id="O2" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Whom Target Lesion Was Sampled</title>
        <description>records if a target lesion was reached during the procedure using the randomised needle or not</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25G FNA Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
          </group>
          <group group_id="O2">
            <title>20G ProCore FNB Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Whom Target Lesion Was Sampled</title>
          <description>records if a target lesion was reached during the procedure using the randomised needle or not</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306"/>
                    <measurement group_id="O2" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Vital Target Cells Per Case, Per Needle Type</title>
        <description>Presence of sufficient vital target cells, as in, target organ cells to provide a diagnosis (yes or no)</description>
        <time_frame>after 27 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25G FNA Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
          </group>
          <group group_id="O2">
            <title>20G ProCore FNB Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Vital Target Cells Per Case, Per Needle Type</title>
          <description>Presence of sufficient vital target cells, as in, target organ cells to provide a diagnosis (yes or no)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The chi-square test (with Yatesâ€™ correction when appropriate) or the Fisher exact test was used to compare the two needle types</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events Per Needle Type</title>
        <description>adverse events per needle type, up to 27 months after procedure</description>
        <time_frame>27 months after procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25G FNA Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
          </group>
          <group group_id="O2">
            <title>20G ProCore FNB Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events Per Needle Type</title>
          <description>adverse events per needle type, up to 27 months after procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diagnostic Yield of the First Needle Pass</title>
        <description>Yield is expressed as sample sufficiency for diagnostic analysis by pathologists, this was either sufficient or not</description>
        <time_frame>after 27 months</time_frame>
        <population>Yield is expressed as sample sufficiency for diagnostic analysis by pathologists, this was either sufficient or not</population>
        <group_list>
          <group group_id="O1">
            <title>25G FNA Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
          </group>
          <group group_id="O2">
            <title>20G ProCore FNB Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Yield of the First Needle Pass</title>
          <description>Yield is expressed as sample sufficiency for diagnostic analysis by pathologists, this was either sufficient or not</description>
          <population>Yield is expressed as sample sufficiency for diagnostic analysis by pathologists, this was either sufficient or not</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>On-site Pathological Evaluation Performed</title>
        <description>Presence of pathologist on site during procedure</description>
        <time_frame>27 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>25G FNA Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
          </group>
          <group group_id="O2">
            <title>20G ProCore FNB Needle</title>
            <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
          </group>
        </group_list>
        <measure>
          <title>On-site Pathological Evaluation Performed</title>
          <description>Presence of pathologist on site during procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>27 months</time_frame>
      <desc>it does not differ, 5 adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>25G FNA Needle</title>
          <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
25G FNA needle</description>
        </group>
        <group group_id="E2">
          <title>20G ProCore FNB Needle</title>
          <description>Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
20G ProCore FNB needle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. P. van Riet</name_or_title>
      <organization>Erasmusm MC University Medical Center Rotterdam</organization>
      <phone>0031648237608</phone>
      <email>p.vanriet@erasmusmc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

